Status:
WITHDRAWN
Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Leukemia, Myeloid, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of the study is to assess the safety of ipilimumab and dasatinib combination therapy in patients with CML
Eligibility Criteria
Inclusion
- Ph+ CML on dasatinib therapy
- Loss of cytogenetic or molecular response while on dasatinib therapy
- On stable dose of dasatinib for a minimum of 12 weeks and with \< 14 day interruption of treatment
Exclusion
- Blast crisis CML
- Autoimmune disease
- Uncontrolled or significant cardiovascular disease
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00732186
Start Date
August 1 2009
End Date
February 1 2011
Last Update
February 17 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University Of Texas, M.D. Anderson Cancer Center
Houston, Texas, United States, 77030